首页 >>2016年02期
流感及其疫苗接种与心血管事件发生风险的关系
作者:姜一梦 张岩

摘要:

心血管疾病等慢病患者患流感后发生心血管事件的风险增高,疾病负担显著高于健康人群。接种流感疫苗是预防流感的有效手段并已被推荐作为心血管疾病的二级预防,但目前心血管疾病患者的疫苗接种率远低于目标值。接种流感疫苗是否可以预防急性心肌梗死及死亡等心血管事件,现有观察性研究和随机对照研究的结果仍存在争议,可能与研究设计、研究对象选择、研究终点设定及样本量等多个因素有关。最新的荟萃研究提示,流感疫苗或可降低心血管事件风险,但还需要大样本的随机对照临床试验来进一步证实并明确疫苗接种策略适用于心血管疾病的预防。

关键词:心血管疾病;流感,人;流感疫苗;接种

Abstract:

Cardiovascular risk and related medical burden due to influenza in patients with chronic disease were higher than those of healthy subjects. As a result, influenza vaccination is recommended as a strategy for secondary prevention in cardiovascular disease by major cardiovascular organizations, but the prevalence of influenza vaccination in these population is still low. Whether influenza vaccine can prevent cardiovascular events such as myocardial infarction and death is still controversial based on current evidences from observational studies and case-control studies, which may result from study desion,subjects selection,outcome definition and sample size issues. Recent meta-analysis showed that influenza vaccination may reduce cardiovascular risk, but large-scale random controlled trials with adequately power should be conducted to confirm these findings as well as the target population for this strategy further.

Key words: Cardiovascular disease;Influenza, human;Influenza vaccines;Vaccination

发表日期:2016/2

引用本文:

图/表:

    暂无图表

参考文献:

[1]胡盛寿.中国心血管病学报告2014[M].北京:中国大百科全书出版社,2015.
[2]YusufS, HawkenS, OunpuuS, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study[J]. Lancet, 2004, 364(9438): 937-952.
[3]World Health Organization. Immunization, Vaccines and Biologicals[EB/OL]. [2015-09-11]. http://www.who. int/immunization/topics/influenza/en/index.html.
[4]BarkerWH, MulloolyJP. Pneumonia and influenza deaths during epidemics:Implications for prevention[J]. Arch Intern Med, 1982, 142(1): 85-89.
[5]Health Protection Agency. Surveillance of influenza and other respiratoryvirusesinthe UK, 2010/2011[EB/OL]. [2015-09-01]. http://www.hpa.org.uk/.
[6]SmeethL, ThomasSL, HallAJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination[J]. N Engl J Med, 2004, 351(25): 2611-2618.
[7]BarnesM, HeywoodAE, MahimboA, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies[J]. Heart, 2015, 101(21): 1738-47. DOI: 10.1136/heartjnl-2015-307691.
[8]Warren-GashC, BhaskaranK, HaywardA, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong[J]. J Infect Dis, 2011, 203(12): 1710-1718. DOI: 10.1093/infdis/jir171.
[9]FengL, ShayDK, JiangY, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008[J]. Bull World Health Organ, 2012, 90(4): 279-288B. DOI: 10.2471/BLT.11.096958.
[10]YuH, FengL, ViboudCG, et al. Regional variation in mortality impact of the 2009 A (H1N1) influenza pandemic in China[J]. Influenza Other Respir Viruses, 2013, 7(6): 1350-1360. DOI: 10.1111/irv.12121.
[11]LiuIF, HuangCC, ChanWL, et al. Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease:a nationwide population-based study[J]. Prev Med, 2012, 54(6): 431-433. DOI: 10.1016/j.ypmed.2012.03.020.
[12]JohnstoneJ, LoebM, TeoKK, et al. Influenza vaccination and major adverse vascular events in high-risk patients[J]. Circulation, 2012, 126(3): 278-286. DOI: 10.1161/CIRCULATIONAHA.111.071100.
[13]MacintyreCR, HeywoodAE, KovoorP, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study[J]. Heart, 2013, 99(24): 1843-1848. DOI: 10.1136/heartjnl-2013-304320.
[14]NaghaviM, BarlasZ, SiadatyS, et al. Association of Influenza vaccination and reduced risk of recurrent myocardial infarction[J]. Circulation, 2000, 102(25): 3039-3045.
[15]GurfinkelEP, Leon de la FuenteR, MendizO, et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study[J]. Eur Heart J, 2004, 25(1): 25-31.
[16]CiszewskiA, BilinskaZT, BrydakLB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study[J]. Eur Heart J, 2008, 29(11): 1350-1358. DOI: 10.1093/eurheartj/ehm581.
[17]LoombaRS, AggarwalS, ShahPH, et al. Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292, 383 patients[J]. J Cardiovasc Pharmacol Ther, 2012, 17(3): 277-283. DOI: 10.1177/1074248411429965.
[18]UdellJA, ZawiR, BhattDL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis[J]. JAMA, 2013, 310(16): 1711-1720. DOI: 10.1001/jama.2013.279206.
[19]ClarC, OseniZ, FlowersN, et al. Influenza vaccines for preventing cardiovascular disease[J]. Cochrane Database Syst Rev, 2015(5): CD005050. DOI: 10.1002/14651858.CD005050.pub3.
[20]ChenJ, LiYT, GuBK, et al. Estimation of the direct cost of treating people aged more than 60 years infected by influenza virus in Shanghai[J]. Asia Pac J Public Health, 2015, 27(2): NP936-946. DOI: 10.1177/1010539512460269.
[21]ZhouL, SituS, HuangT, et al. Direct medical cost of influenza-related hospitalizations among severe acute respiratory infections cases in three provinces in China[J]. PLoS One, 2013, 8(5): e63788. DOI: 10.1371/journal.pone.0063788.
[22]PeasahSK, Azziz-BaumgartnerE, BreeseJ, et al. Influenza cost and cost-effectiveness studies globally--a review[J]. Vaccine, 2013, 31(46): 5339-5348. DOI: 10.1016/j.vaccine.2013.09.013.
[23]OttJJ, Klein BretelerJ, TamJS, et al. Influenza vaccines in low and middle income countries:a systematic review of economic evaluations[J]. Hum Vaccin Immunother, 2013, 9(7): 1500-1511. DOI: 10.4161/hv.24704.
[24]边申溦,马爱霞.我国流感疫苗接种策略经济学评价综述[J].现代商贸工业,2015,36(2):54-55.
[25]SmithSCJr, AllenJ, BlairSN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update: endorsed by the National Heart, Lung, and Blood Institute[J]. Circulation, 2006, 113(19): 2363-2372.
[26]SmithSCJr, BenjaminEJ, BonowRO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation[J]. Circulation, 2011, 124(22): 2458-2473. DOI: 10.1161/CIR.0b013e318235eb4d.
[27]Task Force Members, MontalescotG, SechtemU, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J, 2013, 34(38): 2949-3003. DOI: 10.1093/eurheartj/eht296.
[28]冯录召,杨鹏,张涛,等.中国季节性流感疫苗应用技术指南(2014-2015)[J].中华流行病学杂志,2014,35(12):1295-1319. DOI: 10.3760/cma.j.issn.0254-6450.2014.12.001
[29]AjaniUA, FordES, OkoroCA, et al. Low prevalence of influenza vaccination among people with cardiovascular disease-BRFSS[J]. Am J Prev Med, 2005, 29(5Suppl 1): 31-35.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号